A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Thomas Jefferson University
- Enrollment
- 14
- Locations
- 3
- Primary Endpoint
- Progression-Free Survival (PFS)
Study Overview
Brief Summary
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the tumor cells. Anastrozole is a drug that blocks the production of estrogen in the body. Giving onapristone with anastrozole may work better than anastrozole alone in treating patients with hormone receptor positive endometrial cancer.
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the activity and safety of a pure progesterone receptor (PR) antagonist, extended-release onapristone (onapristone), with anastrozole to treat women with recurrent metastatic estrogen receptor positive (ER+)/progesterone receptor positive (PR+) endometrial carcinoma.
SECONDARY OBJECTIVES:
I. To estimate the disease control rate (DCR). II. To describe duration of response (DOR). III. To evaluate the safety and tolerability. IV. To evaluate quality of life using the Edmonton Symptom Assessment questionnaire.
EXPLORATORY OBJECTIVES:
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age greater than or equal to 18 years old
- •Histologically confirmed diagnosis of endometrial cancer with ER and/or PR expression >= 1% by IHC on archival tissue taken within the prior 3 years or new biopsy if no archival tissue is available. IHC results do not have to be from Thomas Jefferson University
- •Patients who have failed one prior treatment with a platinum/taxane chemotherapy regimen for management of disease
- •* Patients cannot have treatment with more than 2 prior lines of therapy (one line must be platinum/taxane regimen)
- •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.
- •Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension. Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
- •Patients with the following histologic epithelial cell types are eligible:
- •Endometrioid adenocarcinoma
- •Serous adenocarcinoma
- •Undifferentiated carcinoma
- •Clear cell adenocarcinoma
- •Mixed epithelial carcinoma
- •Adenocarcinoma not otherwise specified (NOS)
- •Please note: patients with carcinosarcoma are ineligible for this trial
- •Patients must have had one prior treatment with a platinum/taxane chemotherapy regimen for management of disease
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •Must have a life expectancy of at least 12 weeks as judged by the treating physician
- •Females are only eligible for this study if they are postmenopausal. This is defined as meeting one of the following criteria:
- •S/p total abdominal hysterectomy and bilateral salpingo-oopherectomy
- •Patients who are in menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 55 in the absence of other biological or physiological causes OR women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.
- •Body weight > 30 kg
- •Absolute neutrophil count 1500/ul or more
- •Platelets 100,000/ul or more
- •Hemoglobin 9 g/dl or more
- •Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)
- •Endocrine and targeted therapy protocols usually enroll patients with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) in patients without underlying liver metastasis and < 5.0 x ULN in patients with underlying liver metastasis
- •Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula or measured creatinine clearance using 24 hours urine collection
- •International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
- •All subjects must be able to comprehend and sign a written informed consent document
- •Resolution of all acute toxic effects of prior therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) grade =< 1, with the exception of unresolved grade 2 neuropathy and grade 2 alopecia, which are allowed
- •Patient has recovered from any prior radiotherapy
- •Patients must be able to swallow tablets whole, without crushing
- •Be able to read and speak English
Exclusion Criteria
- •Concurrent or recent chemotherapy, radiotherapy, immunotherapy, or general anesthesia/major surgery within 3 weeks
- •History of prior hormonal therapy (i.e., megestrol acetate, tamoxifen or aromatase inhibitors) for treatment cancer within the past 2 months. Other concurrent hormonal therapy will not be allowed on this trial
- •Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy
- •If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
- •Has received prior systemic anti-cancer therapy including investigational agents within 3 weeks prior to randomization
- •Known brain metastasis which have not been treated or showed stability for >= 6 months
- •Proteinuria > 1+ on urinalysis or > 1 gm/24 hours (hr)
- •Known history of New York Heart Association stage 3 or 4 cardiac disease
- •A pleural or pericardial effusion of greater than or equal to grade 3 severity
- •Women who are pregnant or nursing
- •Has an active infection requiring systemic therapy
- •Use of any prescription medication during the prior 28 days of first onapristone dosing that the investigator judges is likely to interfere with onapristone activity; specifically strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4
- •Patients may not be on a concurrent clinical trial, unless approved by investigator
Arms & Interventions
Treatment (onapristone, anastrozole)
Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
Intervention: Extended-release Onapristone (Drug)
Treatment (onapristone, anastrozole)
Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
Intervention: Anastrozole (Drug)
Treatment (onapristone, anastrozole)
Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
Intervention: Progesterone Receptor Positive ( PGR Positive; PR Positive) (Diagnostic Test)
Treatment (onapristone, anastrozole)
Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
Intervention: Quality-of-Life Assessment (Other)
Treatment (onapristone, anastrozole)
Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
Intervention: Questionnaire Administration (Other)
Treatment (onapristone, anastrozole)
Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
Intervention: Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive) (Diagnostic Test)
Outcomes
Primary Outcomes
Progression-Free Survival (PFS)
Time Frame: At 4 months
4 month PFS is defined as a binary endpoint, from first dose of onapristone and anastrozole to 4 months of therapy as "confirmed progression-free" or "not progression-free" (including cancer progression or censored subjects). Will use the date of first documented disease progression or recurrence, as assessed by using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
Objective response rate (ORR)
Time Frame: Up to 1 year post-treatment
Defined by the percentage of patients with tumor response (complete response \[CR\] or partial response \[PR\]) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Objective Response Rate (ORR)
Time Frame: Up to 1 year post-treatment, up to 36 months total
Defined by the percentage of patients with tumor response (complete response \[CR\] or partial response \[PR\]) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Progression-Free Survival (PFS)
Time Frame: From treatment until disease progression or death, up to 25 months
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Secondary Outcomes
- Time to Response(From randomization to first documented response (CR or PR) in months, assessed up to 1 year post-treatment)
- Duration of Response(From the first date of documented response to progression or death due to endometrial cancer, assessed up to 1 year post-treatment)
- Disease Control Rate(Up to 1 year post-treatment)
- Type, frequency and severity of adverse events and laboratory abnormalities(Up to 30 days post-treatment)
- Quality of Life and pain score(Up to 1 year post-treatment)
- Time to Response(up to 1 yr post treatment)
- Duration of Response in Participants With Complete Response(From the first date of documented response to progression or death due to endometrial cancer, assessed up to 1 year post-treatment)
- Duration of Response in Participants With Partial Response(From the first date of documented response to progression or death due to endometrial cancer, assessed up to 1 year post-treatment)
- Quality of Life Assessed by the Edmonton Symptom Assessment System(Up to 25 months)